BDRX VS KERN Stock Comparison

Performance

BDRX
10/100

BDRX returned -98.01% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

KERN
10/100

KERN returned -81.11% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Volatility

BDRX
71/100

BDRX has had a higher than average amount of volatility over the last 12 months giving it a score of 71 of 100.

KERN
44/100

KERN has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Technicals

BDRX

"Technicals" not found for BDRX

KERN
11/100

KERN receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

BDRX

"Earnings" not found for BDRX

KERN
10/100

KERN has missed earnings 10 times in the last 20 quarters.

Profit

BDRX

"Profit" not found for BDRX

KERN
10/100

Out of the last 20 quarters, KERN has had 2 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Biodexa Pharmaceuticals plc American Depositary Shs Summary

Nasdaq / BDRX

Healthcare

Biotechnology

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Akerna Corp. Common Stock Summary

Nasdaq / KERN

Healthcare

Health Information Services

Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a tool for alcohol brands to analyze their retail sales analytics. In addition, the company operates seed-to-sale platform that offers tracking, reporting, and compliance tools to cannabis cultivators, processors, sellers, and clinics. Further, it provides cannabis cultivation management and compliance software; and cannabis tracking technology that offers seed-to-sale-to-self data. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.

Power up your portfolio